Literature DB >> 12448685

An investigation into the microflora of heroin.

J McLAUCHLIN, V Mithani, F J Bolton, G L Nichols1, M A Bellis1, Q Syed1, R P M Thomson1, J R Ashton1.   

Abstract

In 2000, an unusual increase of morbidity and mortality among illegal injecting drug users in the UK and Ireland was reported and Clostridium novyi was identified as the likely source of the serious infection, although infections due to C. botulinum and Bacillus cereus were also reported. Because heroin was a possibile source of infection, this study investigated the microflora of heroin samples seized in England during 2000 and 2002. Two methods were developed for the examination of the microflora of heroin. The first consisted of suspension of the drug in maximum recovery diluent (MRD) which was inoculated directly into Clostridium Botulinum Isolation Cooked Meat Broth (CBI). The second method rendered the heroin soluble in citric acid, concentrated particulate material (and bacterial cells) by filtration and removed heroin residues by washing with citric acid and phosphate-buffered saline before placing the filter in CBI broth. Duplicate CBI broths from both methods were incubated without heating and after heating at 60 degrees C for 30 min. Subcultures were made after incubation for 7 and 14 days on to eight different solid media. The methods were evaluated with heroin samples spiked with either C. botulinum or C. novyi spore suspensions; recovery of 10 spores in the original sample was demonstrated. Fifty-eight heroin samples were tested by citric acid solubilisation and 34 by the MRD suspension technique. Fifteen different gram-positive species of four genera were recognised. No fungi were isolated. Aerobic endospore-forming bacteria (Bacillus spp. and Paenibacillus macerans) were the predominant microflora isolated and at least one species was isolated from each sample. B. cereus was the most common species and was isolated from 95% of all samples, with B. licheniformis isolated from 40%. Between one and five samples yielded cultures of B. coagulans, B. laterosporus, B. pumilus, B. subtilis and P. macerans. Staphylococcus spp. were isolated from 23 (40%) samples; S. warneri and S. epidermidis were the most common and were cultured from 13 (22%) and 6 (10%) samples respectively. One or two samples yielded cultures of S. aureus, S. capitis and S. haemolyticus. The remainder of the flora detected comprised two samples contaminated with C. perfringens and two samples with either C. sordellii or C. tertium. Multiple bacterial species were isolated from 43 (74%) samples, a single species from the remaining 15. In 13 samples B. cereus alone was isolated, in one B. subtilis alone and in one sample B. pumilus alone. C. botulinum and C. novyi were not isolated from any of the heroin samples. Recommendations for the optimal examination of the microflora of heroin are given.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12448685     DOI: 10.1099/0022-1317-51-11-1001

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  10 in total

1.  Development of a risk reduction intervention to reduce bacterial and viral infections for injection drug users.

Authors:  Kristina T Phillips; Jennifer K Altman; Karen F Corsi; Michael D Stein
Journal:  Subst Use Misuse       Date:  2012-09-27       Impact factor: 2.164

2.  Epidemiological findings and medical, legal, and public health challenges of an investigation of severe soft tissue infections and deaths among injecting drug users -- Ireland, 2000.

Authors:  K Murray-Lillibridge; J Barry; S Reagan; D O'flanagan; G Sayers; C Bergin; E Keenan; S O'briain; P Plunkett; G McMahon; C Keane; P O'sullivan; D Igoe; L Mullen; M Ward; A Smith; M Fischer
Journal:  Epidemiol Infect       Date:  2005-11-29       Impact factor: 2.451

3.  An outbreak in intravenous drug users due to USA300 Latin-American variant community-acquired methicillin-resistant Staphylococcus aureus in France as early as 2007.

Authors:  M Sassi; B Felden; M Revest; P Tattevin; Y Augagneur; P-Y Donnio
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-02       Impact factor: 3.267

4.  Clostridium sordellii lethal toxin is maintained in a multimeric protein complex.

Authors:  Daniel E Voth; Maen Qa'Dan; Elaine E Hamm; Joy M Pelfrey; Jimmy D Ballard
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

5.  Persistent Bacillus cereus Bacteremia in 3 Persons Who Inject Drugs, San Diego, California, USA.

Authors:  Gabrielle Schaefer; Wesley Campbell; Jeffrey Jenks; Cari Beesley; Theodoros Katsivas; Alex Hoffmaster; Sanjay R Mehta; Sharon Reed
Journal:  Emerg Infect Dis       Date:  2016-09       Impact factor: 6.883

6.  Development of a filter to prevent infections with spore-forming bacteria in injecting drug users.

Authors:  Nour Alhusein; Jenny Scott; Barbara Kasprzyk-Hordern; Albert Bolhuis
Journal:  Harm Reduct J       Date:  2016-12-01

7.  Bacillus cereus bacteraemia: comparison between haematologic and nonhaematologic patients.

Authors:  S Tusgul; G Prod'hom; L Senn; R Meuli; P-Y Bochud; S G Giulieri
Journal:  New Microbes New Infect       Date:  2016-11-17

8.  Infections with spore-forming bacteria in persons who inject drugs, 2000-2009.

Authors:  Norah E Palmateer; Vivian D Hope; Kirsty Roy; Andrea Marongiu; Joanne M White; Kathie A Grant; Colin N Ramsay; David J Goldberg; Fortune Ncube
Journal:  Emerg Infect Dis       Date:  2013-01       Impact factor: 6.883

9.  Injectional anthrax at a Scottish district general hospital.

Authors:  D J Inverarity; V M Forrester; J G R Cumming; P J Paterson; R J Campbell; T J G Brooks; G L Carson; J P Ruddy
Journal:  Epidemiol Infect       Date:  2014-07-31       Impact factor: 4.434

10.  A pragmatic harm reduction approach to manage a large outbreak of wound botulism in people who inject drugs, Scotland 2015.

Authors:  Kirsten M A Trayner; Amanda Weir; Andrew McAuley; Gauri Godbole; Corinne Amar; Kathie Grant; Gillian Penrice; Kirsty Roy
Journal:  Harm Reduct J       Date:  2018-07-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.